The effects of cyclic AMP increasing cardiotonics (dopamine, dobutamine, amrinone and milrinone) on the blood flow in most organs were compared using colored microsphere technique in isoflurane-anesthetized dogs. Dopamine increased blood flow in ventricular myocardium. Furthermore dopamine induced the increase in blood flow in intestine and kidney at low to middle dose, but not at high dose. Dobutamine induced the highest increase in blood flow in ventricular myocardium and skeletal muscle among the drugs evaluated at middle and high doses. Amrinone and milrinone increased blood flow in ventricular myocardium almost same with catecholamines, and milrinone decreased vascular resistance moderately in most other organs. Milrinone might be more useful than catecholamines for improvement of congestive heart failure or peripheral circulatory failure accompanied with exceeded vasoconstriction.
Catecholamines (CA) have been most commonly used as cardiotonics for acute heart failure and shock treatment. Dopamine (DA) and dobutamine (DB) induce potent inotropic action through α and β adrenaline receptors on myocardial cell membrane [12, 16, 32] . However, CA may induce tachycardia and hypoxia in myocardium [33] . In addition, prolonged use of CA causes down regulation of myocardial adrenergic receptors resulting in decrease in cardiotonic effects of CA [5] .
Selective phosphodiesteraseIII (PDEIII) inhibitors such as amrinone (AM) and milrinone (ML) increase the intracellular concentration of cyclic adenosine-3, 5-cyclic monophosphate (cAMP) [8] by inhibiting PDEIII, which is a splitting enzyme of cAMP [37] and increase myocardial contractility without activation of adrenergic receptors [1, 2] . Therefore PDEIII inhibitors might act effectively even in the case that CAs do not act adequately due to adrenergic receptor down regulation [6] . Furthermore, PDEIII inhibitors inhibit PDEIII on vascular smooth muscle [30] and exerts vasodilative effects [1, 13] .
Although the systemic cardiovascular effects of CAs and PDEIII inhibitors have been studied widely, the changes in regional blood flow induced by these agents have not been known well partly due to technical difficulty. Radioactive microspheres has been most commonly used for measuring regional blood distribution, because regional blood flow per organ weight in each tissue can be measured simultaneously [14] . Recently, colored microspheres has been used for measuring regional blood flow instead of radioactive agents [36] .
Although, both CAs and PDEIII inhibitors has positive inotropic effect, the changes in blood flow in each organ may be different among the drugs, even if the increase in cardiac output is in same degree. The information about the changes in blood flow in each organ is essential for the choice of the most suitable positive inotropic drug in clinical cases. In the present study, the changes in regional blood distribution were evaluated after administration of DA, DB, AM or ML by using colored microsphere method.
MATERIALS AND METHODS

Animals and animal preparations:
This study was conducted under the guideline of the Animal Care Committee of the University of Tokyo. Twenty-eight healthy beagles were used (age 9.5 to 26 months old, body weight 6.4 to 12.9 kg) in this study. These dogs were divided into four groups (7 dogs each) at random to evaluate four drugs described below. All the procedures including the surgical procedure and experiments were performed under general anesthesia to diminish animal pain and stress.
Anesthesia was induced with isoflurane (ISO; Forane ® , Dainabot Co., Ltd., Osaka) via facemask and animals were intubated endotracheally for artificial ventilation with ISO and 100% O 2 . End-tidal ISO (EtISO) concentration was maintained at 1.95 +/-0.03% (=1.50 to 1.55 MAC), body temperature at 38.0 +/-0.3°C, respiratory rate at 12 breaths per min, end-tidal CO 2 (EtCO 2 ) at 30 +/-3 mmHg and airway pressure under 20 cmH 2 O throughout the measuring period. After animals were positioned in left lateral recumbency, lateral thoracotomy was performed and 1.5 mm external diameter Teflon catheter (F-8006-03 Teflon tube, Flon Industry Co., Ltd., Tokyo) was placed in the left atrial appendage for the injection of colored microsphere. Another 1.5 mm external diameter Teflon catheter was inserted into the distal aorta via the left femoral artery for the measurement of arterial pressure and for collecting reference blood.
Drugs: Two CAs including dopamine HCl (DA: Inovan ® , Kyowa Hakko Kogyo Co., Ltd., Tokyo) and dobutamine HCl (DB: Dobutrex ® , Shionogi & Co., Ltd., Osaka), and two PDEIII inhibitors including amrinone (AM: Amcoral ® , Meiji Seika Kaisha, Co., Ltd. Tokyo) and milrinone (ML; Milrilla ® , Yamanouchi Pharmaceutical Co., Ltd., Tokyo) were used at three different doses (low, middle and high) in this study. DA and DB were diluted hundredfold with physiological saline (PS) for maintenance use. AM was diluted fivefold with PS for maintenance dose, and ML was diluted fivefold with PS for loading dose and tenfold for maintenance dose.
Loading dose and/or maintenance dose of each drug is shown in Table 1 . Loading and maintenance doses of AM and ML were calculated by the method reported by Wagner et al. [35] . In our previous study, four drugs used here exerted the same degree of increase in cardiac output at each maintenance dose level [31] . All the drugs were injected intravenously through a catheter placed in cephalic vein.
Colored microsphere technique: Regional blood flow in each organ was measured using colored microspheres (CM) as blood flow per tissue weight. One ml CM solution contains about 5,000 white, yellow, eosin, red, violet or blue microspheres with 0.05% Tween80 and 0.01% thimeorsal (DYE-TRAK, 15.0 +/-0.45 µm diameter, Triton Technology Inc., San Diego, CA, U.S.A.). Tissue samples collected were digested with sufficient volume of 4M KOH digestive solution containing 2% polyoxyethylene (20) sorbitan monooleate (Wako Pure Chemical Industries, Ltd., Osaka) in plastic tubes. Blood samples were digested with 6 m l of 16M KOH in plastic tubes. From each digested blood and tissue sample CM was collected using a 10 µm diameter pore polyester membrane filter under vacuum suction. The filter with CM was put into a glass tube and 200 µl of dimethylformamide was added, stirred and extracted dyestuff from CM. Photometric absorption of each dyestuff solution extracted was measured by a spectrophotometer (UV-160A: Shimadzu Co., Ltd., Kyoto). The results obtained were analyzed with the computer program (MISS: Triton Technology Inc.), and each regional blood flow was calculated with the following formula. Qm = (Am × Qr)/Ar Qm: regional blood flow (ml/g/min), Am: photometric absorbance for CM in 1 g of tissue sample (AU), Qr: reference blood collection rate (ml/min), Ar: photometric absorbance for whole CM in reference blood (AU) Regional vascular resistance (VR) of each tissue was calculated by dividing mean arterial pressure (MAP: mmHg) by blood flow.
Experimental Protocol: After animal condition was stabilized, heart rate (HR: beats/min), electrocardiogram (ECG), systolic arterial pressure (SAP: mmHg), MAP and diastolic arterial pressure (DAP: mmHg) were measured or recorded as baseline values. Rate pressure product (RPP: mmHg/ min) was calculated from the value obtained above with the following formula.
RPP= SAP × HR
Following the measurements, one ml white, yellow, eosin, red, violet or blue CM, diluted with 4 ml PS solution was injected into left atrium in 10 sec and flushed twice with 5 ml PS in 25 sec. Reference blood was collected at a rate of 4.50 ml/min from 15 sec before the injection of CM for 130 sec (total 9.75 ml) from distal aorta using a diffusion pump (FP-W-100, Toyo Sangyo Inc., Toyama).
More than 10 min after the first injection of CM and after all hemodynamic parameters were stabilized, low dose of DA, DB, AM or ML were administered at the rate described in Table 1 . AM and ML were administered at loading dose for 5 min and then switched to the maintenance doses. After continuous administration of each drug at low dose for 30 min and hemodynamic parameters were stabilized, HR, ECG and arterial pressure (AP) were measured and recorded. After these measurements, second injection of CM using different color spheres was performed and reference blood was collected in a same manner described above. Then the middle doses of drugs were administered. After the hemodynamic parameters measurements, third injection of CM using different color spheres was performed. Same measurements and fourth injection of CM using different color spheres were performed at high dose in a same manner described above. After all experimental protocol was performed, anesthesia was deepened and KCl was injected to euthanize the animals.
Soon after the euthanasia, 2 to 15 g of cerebral cortex, cerebellum, eye, lung, heart (right and left ventricular myocardium), liver, kidney (cortex), pancreas, stomach, small intestine (jejunum) and muscle (quadriceps) tissue were collected for evaluation of regional blood flow at each dose level.
Statistics: Statistical analysis was performed using a com- puter program (Stat View-J4.5: Abacus Concepts Inc., Barkley, CA, U.S.A.). Two-factor analysis of variance for repeated measures was used to compare the low, middle and high dose values with pre-administration (baseline) value. When the interaction was significant, the within-subject dose effects on the variables were evaluated with one-factor analysis of variance for repeated measures followed by post hoc test (Scheffe's F test). Values of p < 0.05 were considered as statistically significant. Table 2 shows the changes in cardiovascular parameters in each group. Abnormal ECG (bigeminy) was recorded in one dog, which appeared five min after the start of middle dose of DA for about 20 min.
RESULTS
HR tended to increase at middle and high dose of any drugs and increased significantly as compared with the baseline value at high dose of DB, AM and ML. AP did not change by administration of DA at low dose, but increased significantly at high dose. AP did not change significantly by administration of DB. AM and ML tended to decrease DAP and MAP at higher doses but the changes were not significant. RPP did not change significantly by the adminis-tration of AM and ML. In contrast, RPP increased significantly by the administration of DA and DB at high dose.
The change in tissue blood flow of each organ observed in this study is shown in Table 3 . Table 4 shows the changes in calculated VR. As most photometric absorbance data with white CM were abnormally low by suspected technical error, all these data were not adopted in this study.
Brain (cerebral cortex, cerebellum): Brain blood flow tended to decrease and VR tended to increase in a dose dependent manner after administration of DA and DB. Cerebral cortex blood flow decreased significantly from the baseline value at high dose of DB, and cerebellum blood flow decreased significantly from the baseline value at middle and high dose of DA and at high dose of DB. Cerebral cortex and cerebellum VR increased significantly from the baseline value at high dose of DA and DB. Brain blood flow also tended to decrease after administration of AM and ML, however no significant changes were observed. VR hardly changed after AM and ML.
Heart: Blood flow in right and left ventricular myocardium increased dose dependently and the values at high dose of any drugs were significantly different from the baseline values. Blood flow in myocardium increased mostly with DB among the drugs tested and showed significant difference from the baseline value even at middle dose. VR with DA did not change significantly, while VR at middle dose of DB and ML and at high dose of DB, AM and ML decreased significantly from the baseline value.
Lung (bronchial artery): Blood flow in lung through bronchial artery tended to decrease after administration of DA dose dependently, and the value at high dose was significantly lower than the baseline value. Although blood flow with DB showed similar tendency as with DA, no significant change was observed. No significant changes were observed with AM and ML. VR increased significantly at high dose of DA and DB, while VR did not change significantly at any dose of AM and ML. The change was much stronger with DA than with DB.
Liver (hepatic artery): Although the liver blood flow through hepatic artery tended to decrease after administration of DA and to increase after ML in a dose dependent manner, no significant changes were observed with any drugs at any doses.
Stomach, Small Intestine and Pancreas: Blood flow in stomach at middle dose of DA increased significantly from the baseline value, but decreased at high dose. VR showed contrast changes against blood flow changes, but the changes were not significant. DA tended to increase blood flow in stomach, small intestine and pancreas but no significant change were observed. Blood flow increased in stomach, small intestine and pancreas at low dose of DB, but changes were not significant. VR decreased significantly from the baseline value in small intestine at high dose and in pancreas at middle and high doses of ML. The changes in blood flow in stomach, small intestine and pancreas with AM and ML were small as compared with the changes with DA or DB, and no significant changes were observed at any dose of both drugs.
Kidney (cortex): Blood flow in kidney cortex tended to increase dose dependently at low and middle doses of DA, but the changes were not significant. VR showed contrast changes against blood flow changes after administration of DA. Blood flow in kidney cortex did not change significantly after administration of DB, AM and ML.
Muscle (Quadriceps): Blood flow increased and VR decreased dose dependently in quadriceps muscle after administration of DB. Blood flow and VR significantly changed from the baseline value at high dose of DB. AM and ML tended to increase blood flow but the changes were mild. Blood flow in quadriceps muscle after administration of DA, AM and ML did not change significantly at any doses.
Eye: Blood flow in eye increased from the baseline value at any doses of DA. Blood flow in eye hardly changed after administration of DB, AM and ML.
DISCUSSION
In this study the dogs were anesthetized with ISO to minimize animal pain and stress. ISO has been reported to change HR, AP, CO, systemic vascular resistance and other cardiovascular parameters dose dependently [11, 20, 38] . Although ISO would have exerted significant effects on the results obtained in this study, scientific evaluation of results would be possible because EtISO was maintained at almost same level throughout the experiments.
In this study we examined the effects of DA, DB, AM and ML at hyperoxemic condition by using 100% O 2 to evaluate the dose dependency which needed anesthesia for relatively long time. However most clinical cases with acute heart failure or in shock would have hypoxemia that may influence the effects of these drugs used here. Farther investigations would be needed to clarify this point.
In this study, HR increased significantly after administration of DB, AM and ML. CAs increase HR mainly by stimulating β 1 adrenergic receptor on myocardial cells [32] , but increase in HR at high dose of DA would be depressed as compared with DB due to the baroreflex induced by vasoconstriction through the α adrenergic receptor activation by DA. Increase in HR with AM and ML might be induced partially by baroreceptor reflex that would be induced by decrease in AP, though ISO suppresses baroreceptor reflex [3] .
MAP increased significantly at high dose of DA, while MAP did not change or tended to decrease at high dose of DB, AM and ML. It has been reported DA constricts peripheral vasculature at high dose through activation of α adrenergic receptor, partially releasing endogenous NE [25] , while DB induces rather vasodilatation through activation of β adrenergic receptor [4, 27] . AM and ML decrease AP through the vasodilatation by inhibition of PDEIII [1, 13] overcoming the increase in cardiac output. As a result, RPP increased significantly at high dose of DA and DB while did not change with AM and ML. Those systemic cardiovascular changes observed in this study corresponded to our previous study in which same four drugs were evaluated at the same three dose levels. In that study, four drugs exerted the same degree of increase in cardiac output at each level [31] . Although we did not measure cardiac output actually in this study, we assumed that each drugs would have exerted the same degree of increase in cardiac output at same dose level (low, middle, high) as the previous report.
We used CM technique to measure regional blood flow and VR in this study. This technique enabled to measure blood flow of all organs simultaneously and repeatedly, however the dispersion of data among the individuals was relatively large. Although CM technique is easy to be performed, some technical problems such as the risk of losing CM during filtration process or overlapping of the extract have been reported [15, 22, 36] .
DA has been reported to decrease cerebral blood flow slightly at low dose and to increase at middle dose by vasodilatation through dopaminergic receptor activation, but to decrease again at higher dose by vasoconstriction through α adrenergic receptor and/or serotonin receptor activation [34] . In this study, DA increased VR of cerebral and cerebellum by vasoconstriction at higher doses and these changes would have induced decrease in brain blood flow at higher dose. Although DB has been known as a vasodilator, cerebral and cerebellum VR increased after administration and cerebral and cerebellum blood flow decreased at high dose. The decrease in blood flow in these organs would have partially caused by the changes in distribution of blood in whole body. Farther investigations would be needed to clarify the mechanism of these changes. As this study was performed using dogs with normal cardiovascular function, it was unclear that the decrease in brain blood flow by DA and DB at middle dose would occur in dogs with impaired cardiovascular function. However, CA should not be used at high dose in shock or severe cardiac failure patients.
DA increased myocardial blood flow less than DB in this study, and DB exerted most significant increase in myocardial blood flow among the drugs examined in this study. Although DA exerted coronary arterial vasodilatation through the activation of DA 1 receptors at low dose [19] , DA would have increased myocardial blood flow less than DB due to less vasodilatation caused by α adrenergic receptor mediated vasoconstriction at high dose [7] . The most significant increase in myocardial blood flow with DB might be caused by coronary arterial vasodilatation through the activation of β adrenergic receptor [27] . RPP, which is a reliable indicator of myocardial oxygen consumption, did not change with AM and ML, while the changes in myocardial blood flow after administration of AM and ML were similar to those with DA. These results indicate AM, ML or lower dose of DB would be recommended to improve myocardial blood flow.
Pulmonary blood flow is delivered through pulmonary artery and bronchial artery. As CM was injected into left atrium to measure arterial blood flow in each organ, limited information of pulmonary blood flow (through bronchial artery) was obtained in this study. Although bronchial arterial blood flow might have less effect on lung circulation than pulmonary arterial blood flow, bronchial arterial blood flow is important to water transport to bronchial mucosa [29] . Lung blood flow through bronchial artery decreased and VR increased significantly from the baseline value at high dose of DA [10] . This could be caused by vasoconstriction through α adrenergic receptor activation [24] . In contrast, though it was not significant, lung blood flow through bronchial artery increased and VR decreased by AM and ML dose-dependently. We [31] and others [17] have reported that AM and ML induced reduction of pulmonary vascular resistance and pulmonary arterial pressure while increasing cardiac output. AM and ML might improve pulmonary circulation in the dogs with facilitating pulmonary blood circulation. As described above CM technique detected only arterial blood flow, blood flow in liver was evaluated by only through hepatic artery [9] . In this study arterial blood flow in liver tended to decrease with dopamine. Liver accepts blood supply through hepatic artery and portal vein. Proportion of hepatic blood flow through hepatic artery and through portal vein is approxi-mately 1:2 to 1:3 under 1.5 MAC ISO anesthesia [21] . However arterial blood contains more volume of oxygen and hepatic artery supplies half of total oxygen transporting to liver [18] . It was reported that DA and DB increased portal blood flow and decreased hepatic arterial blood flow, and total hepatic oxygen delivery did not change [18] . Thus, hepatic oxygen delivery would not have decreased even with dopamine. In contrast, ML increased hepatic arterial blood flow in this study. ML may be useful for improvement of blood supply in liver in cases with hepatic failure.
DA has been reported to increase mesentery blood flow thorough DA 1 receptor activation [39] . DB has been reported to increase blood flow of digestive organs and prevent a fall of pH in digestive tubes [26] . Low or middle dose of DA or DB may be recommended to improve blood flow in gastro-intestinal tract.
DA has been reported to act on DA 1 receptor on renal vascular beds resulting in vasodilatation and increase in renal blood flow at lower dose. However the effects of DA on renal blood flow may be reduced by α receptor activation at higher dose [23] . On the other hand, changes in renal blood flow with DB, AM and ML were small [13, 28] . Low to middle dose of DA would be effective to improve renal blood flow.
DB would have increased blood flow and decreased VR in muscle by β 2 adrenergic receptor stimulation [24] . DB would be the suitable drug when the maintenance or improvement of muscle blood flow is a major concern.
In conclusion, DA increased blood flow in ventricular myocardium dose dependently and induced the most increase in blood flow in kidney among the drugs evaluated. With increase in AP, DA would be preferable to use in the heart failure animal with low AP at low to middle doses. But with significant increase in RPP and cerebral VR at high dose, DA should not be use in the constrictive heart failure. DB induced the highest increase in blood flow in ventricular myocardium and skeletal muscle among the drugs evaluated. Although it was not significant, increase in gastrointestinal blood flow with DB should be noted. DB might be useful in most low cardiac output animal. But, with significant increase in RPP and cerebral VR, DB should not be use at high dose. AM and ML increased blood flow in ventricular myocardium almost same with CA, and ML decreased VR moderately in most other organs. ML might be more useful than CA for improvement of congestive heart failure or peripheral circulatory failure with high VR. AM and ML should not be use alone in the animal with low AP or with low blood volume.
